UgeneX
AviadoBio Secures Option to Develop Rare Eye Disease Gene Therapy UGX-202 in $413 Million Deal with China’s UgeneX
AviadoBio; UgeneX; UGX-202; optogenetics; gene therapy; retinitis pigmentosa; China; $413 million deal
Actionable Insights Powered by AI
AviadoBio; UgeneX; UGX-202; optogenetics; gene therapy; retinitis pigmentosa; China; $413 million deal